The Vanguard Group 13D and 13G filings for Relay Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-07-29 2:22 pm Sale |
2025-06-30 | 13G | Relay Therapeutics, Inc. RLAY |
The Vanguard Group | 9,379,851 5.470% |
-2,725,569 (-22.52%) |
Filing |
| 2025-04-30 11:12 am Purchase |
2025-03-31 | 13G | Relay Therapeutics, Inc. RLAY |
The Vanguard Group | 12,105,420 7.140% |
1,455,033 (+13.66%) |
Filing |
| 2024-02-13 5:13 pm Purchase |
2023-12-29 | 13G | Relay Therapeutics, Inc. RLAY |
The Vanguard Group | 10,650,387 8.640% |
266,169 (+2.56%) |
Filing |
| 2023-02-09 11:30 am Purchase |
2022-12-30 | 13G | Relay Therapeutics, Inc. RLAY |
The Vanguard Group | 10,384,218 8.590% |
4,185,776 (+67.53%) |
Filing |
| 2022-02-10 08:32 am Purchase |
2021-12-31 | 13G | Relay Therapeutics, Inc. RLAY |
The Vanguard Group | 6,198,442 5.740% |
6,198,442 (New Position) |
Filing |